Engineered T cells for cancer therapy

Cancer Immunology, Immunotherapy

Volumn 63, Issue 9, 2014, Pages 969-975

  June, Carl H ^a,b   Maus, Marcela V ^a   Plesa, Gabriela ^a   Johnson, Laura A ^a,b   Zhao, Yangbing ^a,b   Levine, Bruce L ^a,b   Grupp, Stephan A ^a,c   Porter, David L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

19th Danish Cancer Society Symposium; Adoptive cell transfer; Chimeric antigen receptor; Gene transfer; Leukemia

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; APLASIA; B CELL APLASIA; BILIARY TRACT DISEASE; CANCER CELL; CANCER IMMUNOTHERAPY; CELL ENGINEERING; CELLULAR IMMUNITY; CYTOKINE RELEASE SYNDROME; HUMAN; MACROPHAGE ACTIVATION SYNDROME; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYNTHETIC BIOLOGY; T LYMPHOCYTE; TUMOR LYSIS SYNDROME; ANIMAL; GENETIC ENGINEERING; GENETICS; IMMUNOLOGY; PROCEDURES;

ANIMALS; GENETIC ENGINEERING; HUMANS; IMMUNOTHERAPY, ADOPTIVE; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 84906937939     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-014-1568-1     Document Type: Review

References (54)

1. Drake CG, Jaffee E, Pardoll DM (2006) Mechanisms of immune evasion by tumors. Adv Immunol 90:51-81 (Pubitemid 43765799)
2. Ho WY, Blattman JN, Dossett ML, Yee C, Greenberg PD (2003) Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell 3:431-437 (Pubitemid 38340289)
3. Kalos M, June CH (2013) Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 39:49-60
4. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP et al (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314:126-129 (Pubitemid 44547756)
5. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, Kammula US, Royal RE, Sherry RM, Wunderlich JR et al (2009) Gene therapy with human and mouse T cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114:535-546
6. Eshhar Z, Waks T, Bendavid A, Schindler DG (2001) Functional expression of chimeric receptor genes in human T cells. J Immunol Methods 248:67-76 (Pubitemid 32167025)
7. Barrett DM, Singh N, Porter DL, Grupp SA, June CH (2014) Chimeric antigen receptor therapy for cancer. Annu Rev Med 65:333-347
8. Aleksic M, Liddy N, Molloy PE, Pumphrey N, Vuidepot A, Chang KM, Jakobsen BK (2012) Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies. Eur J Immunol 42:3174-3179
9. Simpson A, Caballero O, Jungbluth A, Chen Y, Old L (2005) Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 5:615-625 (Pubitemid 41081387)
10. Zhao Y, Zheng Z, Robbins PF, Khong HT, Rosenberg SA, Morgan RA (2005) Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. J Immunol 174:4415-4423 (Pubitemid 40396025)
11. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL (2011) Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29:917
12. Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V, Bianchi FC, Grand F, Brewer JE, Gupta M, Plesa G et al (2013) Identification of a titin-derived HLA-A1-presented peptide as a crossreactive target for engineered MAGE A3-Directed T cells. Sci Transl Med 5(197):197ra103. doi:10.1126/scitranslmed. 3006034
13. Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, Litzky L, Bagg A, Carreno BM, Cimino PJ et al (2013) Cardiovascular toxicity and titin cross-reactivity of affinity enhanced T cells in myeloma and melanoma. Blood 122:863-871
14. Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM et al (2013) Cancer regression and neurological toxicity Following anti-MAGE-A3 TCR gene therapy. J Immunother 36:133-151
15. Irving BA, Weiss A (1991) The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell 64:891-901 (Pubitemid 121001177)
16. Romeo C, Seed B (1991) Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides. Cell 64:1037-1046 (Pubitemid 121001190)
17. Letourneur F, Klausner RD (1991) T-cell and basophil activation through the cytoplasmic tail of T-cell-receptor zeta family proteins. Proc Natl Acad Sci USA 88:8905-8909 (Pubitemid 21915538)
18. Mitsuyasu RT, Anton P, Deeks SG, Scadden DT, Connick E, Downs MT, Bakker A, Roberts MR, June CH, Jalali S et al (2000) Prolonged survival and tissue trafficking following adoptive transfer of CD4 z gene-modified autologous CD4+ and CD8+ T cells in HIV-infected subjects. Blood 96:785-793 (Pubitemid 30616838)
19. Scholler J, Brady T, Binder-Scholl G, Hwang W-T, Plesa G, Hege K, Vogel A, Kalos M, Riley J, Deeks S et al (2012) Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med 4(132):132Ra153. doi:10.1126/scitranslmed.3003761
20. McGuinness RP, Ge Y, Patel SD, Kashmiri SV, Lee HS, Hand PH, Schlom J, Finer MH, McArthur JG (1999) Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor. Hum Gene Ther 10:165-173 (Pubitemid 29070631)
21. Finney HM, Lawson ADG, Bebbington CR, Weir ANC (1998) Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol 161:2791-2797 (Pubitemid 28425698)
22. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, White DE, Wunderlich JR, Canevari S, Rogers-Freezer L et al (2006) A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 12:6106-6115 (Pubitemid 44703776)
23. Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R, Gratama JW, Stoter G, Oosterwijk E (2006) Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 24:e20-e22
24. Kochenderfer J, Wilson W, Janik J, Dudley M, Stetler-Stevenson M, Feldman S, Maric I, Raffeld M, Nathan D, Lanier B et al (2010) Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells geneticallyengineered to recognize CD19. Blood 116:4099-4102
25. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH (2011) T cells expressing chimeric receptors establish memory and potent antitumor effects in patients with advanced leukemia. Sci Transl Med 3(95):95ra73. doi:10.1126/scitranslmed.3002842
26. Porter DL, Levine BL, Kalos M, Bagg A, June CH (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365:725-733
27. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter D, Rheingold S, Teachey D, Chew A, Hauck B, Wright J et al (2013) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368:1509-1518
28. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M et al (2013) CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 5(177):177ra138. doi:10.1126/ scitranslmed.3005930
29. Effros RB, Pawelec G (1997) Replicative senescence of T cells: does the Hayflick Limit lead to immune exhaustion? Immunol Today 18:450-454 (Pubitemid 27381988)
30. Brentjens R, Rivière I, Park J, Davila M, Wang X, Stefanski J, Taylor C, Yeh R, Bartido S, Borquez-Ojeda O et al (2011) Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118:4817-4828
31. Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, Kamble RT, Bollard CM, Gee AP, Mei Z et al (2011) CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 121:1822-1825
32. Morgan R, Yang J, Kitano M, Dudley M, Laurencot C, Rosenberg S (2010) Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18:843-851
33. Jena B, Dotti G, Cooper L (2010) Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 116:1035-1044
34. Maus MV, Grupp SA, Porter DL, June CH (2014) Antibody modified T cells: CARs take the front seat for hematologic malignancies. Blood 123:2625-2635
35. Vera J, Savoldo B, Vigouroux S, Biagi E, Pule M, Rossig C, Wu J, Heslop HE, Rooney CM, Brenner MK et al (2006) T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood 108:3890-3897 (Pubitemid 44864573)
36. Barrett DM, Teachey DT, Grupp SA (2014) Toxicity management for patients receiving novel T-cell engaging therapies. Curr Opin Pediatr 26:43-49
37. Tang Y, Xu X, Song H, Yang S, Shi S, Wei J, Pan B, Zhao F, Liao C, Luo C (2008) Early diagnostic and prognostic significance of a specific Th1/Th2 cytokine pattern in children with haemophagocytic syndrome. Br J Haematol 143:84-91
38. Sieni E, Cetica V, Piccin A, Gherlinzoni F, Sasso FC, Rabusin M, Attard L, Bosi A, Pende D, Moretta L et al (2012) Familial hemophagocytic lymphohistiocytosis may present during adulthood: clinical and genetic features of a small series. PLoS One 7:e44649
39. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM et al (2012) B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119:2709-2720
40. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung S, Stefanski J, Borquez-Ojeda O, Olszewska M et al (2014) Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 6(224):224ra225. doi:10.1126/scitranslmed.3008226
41. Saha B, Harlan DM, Lee KP, June CH, Abe R (1996) Protection against lethal toxic shock by targeted disruption of the CD28 gene. J Exp Med 183:2675-2680 (Pubitemid 26192377)
42. Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Topp MS, Gokbuget N, Neumann S, Goebeler M, Viardot A et al (2012) Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 119:6226-6233
43. Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Seif AE, Nichols KE, Suppa EK, Kalos M, Berg RA et al (2013) Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine directed therapy. Blood 121:5154-5157
44. Davis MM, Krogsgaard M, Huse M, Huppa J, Lillemeier BF, Li QJ (2007) T cells as a self-referential, sensory organ. Annu Rev Immunol 25:681-695 (Pubitemid 46697921)
45. Stone JD, Aggen DH, Schietinger A, Schreiber H, Kranz DM (2012) A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell engagers (BiTEs). Oncoimmunology 1:863-873
46. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S (2000) Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74:181-273
47. Vitale M, Pelusi G, Taroni B, Gobbi G, Micheloni C, Rezzani R, Donato F, Wang X, Ferrone S (2005) HLA class I antigen downregulation in primary ovary carcinoma lesions: association with disease stage. Clin Cancer Res 11:67-72 (Pubitemid 40075779)
48. Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, Varela-Rohena A, Haines KM, Heitjan DF, Albelda SM et al (2009) Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci USA 106:3360-3365
49. Bendle GM, Linnemann C, Bies L, Song JY, Schumacher TN (2013) Blockade of TGF-beta signaling greatly enhances the efficacy of TCR gene therapy of cancer. J Immunol 191:3232-3239
50. Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, Chew A, Zhao Y, Levine BL, Albelda SM et al (2014) Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res 2:112-120
51. John LB, Devaud C, Duong CM, Yong C, Beavis PA, Haynes NM, Chow MT, Smyth MJ, Kershaw MH, Darcy PK (2013) Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res 19(20):5636-5646
52. Levine BL, June CH (2013) Perspective: assembly line immunotherapy. Nature 498:S17
53. Provasi E, Genovese P, Lombardo A, Magnani Z, Liu PQ, Reik A, Chu V, Paschon DE, Zhang L, Kuball J et al (2012) Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat Med 18:807-815
54. Torikai H, Reik A, Soldner F, Warren EH, Yuen C, Zhou Y, Crossland DL, Huls H, Littman N, Zhang Z et al (2013) Toward eliminating HLA class I expression to generate universal cells from allogeneic donors. Blood 122:1341-1349